Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02233192 · ClinicalTrials.gov registry record
PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples
A clinical trial, sponsored by Boston Medical Center.
- Completed
- Registry status
- 50
- Enrollment target
NCT02233192 is a clinical trial that has completed, run by Boston Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT02233192 has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to observe patient response to current clinical practice utilizing TRUVADA (emtricitabine and tenofovir disoproxil fumarate) for Pre-Exposure Prophylaxis (PrEP) amongst HIV serodiscordant couples desiring to conceive across four U.S. cities that are currently offering this method as standard of care. This study is an observational cohort study, which will test the feasibility and acceptability of PrEP for conception, while examining the challenges and generalizability of this current medical practice. The CDC recently released formal clinical practice guidelines for the use of PrEP in the United States. For high-risk serodiscordant heterosexual couples using PrEP during conception, the guidelines state, "PrEP use periconception and during pregnancy by the uninfected partner may offer an additional tool to reduce the risk of sexual HIV acquisition. Both the FDA labeling information and the perinatal antiretroviral treatment guidelines permit this use" (CDC 2014).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02233192
The ClinicalTrials.gov registry entry for NCT02233192 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02233192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02233192 about?
NCT02233192 is a clinical study titled "PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples". The purpose of this study is to observe patient response to current clinical practice utilizing TRUVADA (emtricitabine and tenofovir disoproxil fumarate) for Pre-Exposure Prophylaxis (PrEP) amongst HIV serodiscordant couples desiring to conceive across four U.S. cities that are currently offering th...
What is the current status of trial NCT02233192?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2014-07. Estimated completion is 2017-06-15.
Who is sponsoring clinical trial NCT02233192?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.